Zulassungsempfehlung für Ocrelizumab
Crossref DOI link: https://doi.org/10.1007/s15005-018-2482-4
Published Online: 2018-01-22
Published Print: 2018-01
Update policy: https://doi.org/10.1007/springer_crossmark_policy
red,
